Progress in Medicinal Chemistry

Erscheinungsjahr 2019
ISBN: 978-0-444-64277-6
Verlag: ELSEVIER

Buch, Englisch, Band 58, 197 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 435 g

Reihe: Progress in Medicinal Chemistr

Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery - A Special Challenge?, and SMN2 gene splicing modifier, and more.

Zielgruppe

<p>Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes</p>

Autoren/Hrsg.

Witty, David R.

Cox, Brian

Weitere Mitwirkende

Witty, David R.

Cox, Brian

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie

Inhaltsverzeichnis

1. Covalent binders in drug discovery Maria A. Argiriadi, Aleksandra Baranczak, Michael M. Friedman, Julia Gavrilyuk, Adrian D. Hobson, Jonathan J. Hulce, Sami Osman, Noel S. Wilson and Anil Vasudevan 2. Amyotrophic lateral sclerosis Klara Valko and Lukasz Ciesla 3. Rewriting the (tran)script: Application to spinal muscular atrophy Hasane Ratni, Lutz Mueller and Martin Ebeling 4. Natural product drug delivery: A special challenge? Neil J. Press, Emilie Joly and Peter Ertl

Über Autor(innen)

Cox, Brian
Professor Brian Cox is at University of Sussex, Brighton, UK

Witty, David R.
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.